Nuvectis Pharma, Inc (NVCT) Files IPO Registration Statement
Get Alerts NVCT Hot Sheet
Join SI Premium – FREE
Nuvectis Pharma, Inc (NASDAQ: NVCT) files IPO registration statement.
The company describes itself as: "We are a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious unmet medical needs in oncology. We rely on our core competencies of target selection, drug profiling, and clinical and regulatory execution to build a pipeline of anticancer targeted-therapy drugs. Improved genetic sequencing and understanding of cancers’ RNA, DNA and protein abnormalities has led to the discovery and characterization of novel oncogenic genetic mutations and alterations that were previously unknown, unaddressed, unsuccessfully targeted or overlooked. We believe that these advancements represent a fundamental change in the development of targeted therapies and will increasingly lead to tumor agnostic approaches whereby cancers will be characterized for treatment based on genetic signatures, such as a certain mutation, rather than in a tissue-specific manner. We are currently developing two preclinical drug candidates with the lead candidate expected to begin a Phase 1 clinical trial in the fourth quarter of 2021."
ThinkEquity will serve as lead underwriter.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Junee Ltd (JUNE) Prices 2M Share IPO at $4/sh
- Intrepid Potash (IPI) Grants CEO Temporary Medical Leave of Abscence
- Rubrik (RBRK) Files for 23M Share IPO at $28-$31/sh
Create E-mail Alert Related Categories
Corporate News, IPOsRelated Entities
ThinkEquity, IPOSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!